Zobrazeno 1 - 10
of 147
pro vyhledávání: '"Koji, Nishikawa"'
Autor:
Toshio Arai, Seisuke Saito, Takahiro Kinebuchi, Koji Nishikawa, Yasuyuki Morishima, Hiromu Sugiyama
Publikováno v:
Case Reports in Gastroenterology, Vol 18, Iss 1, Pp 327-332 (2024)
Introduction: Anisakiasis is a parasitic disease caused by larvae from anisakid nematodes. In recent years, there has been an increase in cases of anisakiasis, a relatively uncommon medical condition. Case Presentation: A 93-year-old woman with chron
Externí odkaz:
https://doaj.org/article/f7d9740b704d470bb6f086369edfbc04
Autor:
Toshio Arai, Takehito Kunogi, Takahiro Kinebuchi, Yasuhiro Nakano, Koji Nishikawa, Hiromu Sugiyama
Publikováno v:
Case Reports in Gastroenterology, Vol 17, Iss 1, Pp 321-326 (2023)
Anisakiasis is a parasitic disease caused by the ingestion of raw or uncooked seafood infected with third-stage larvae of anisakid nematodes. Generally, the larvae parasites live at the surface of the mucosa, but in this case, the larva deeply invade
Externí odkaz:
https://doaj.org/article/c9538c6e802248b39f4e8d455fe41cdf
Publikováno v:
Cancers, Vol 16, Iss 2, p 320 (2024)
In this retrospective study, we investigated the potential application of serum stem cell growth factor beta (SCGF-β) as a biomarker for predicting the therapeutic response and prognosis in patients with hepatocellular carcinoma (HCC) undergoing ate
Externí odkaz:
https://doaj.org/article/efde027cf8fd45a1b9c39878ac3bcbba
Autor:
Masamichi Kimura, Koji Nishikawa, Yosuke Osawa, Jun Imamura, Kenzaburo Yamaji, Kenichi Harada, Hiroshi Yatsuhashi, Kazumoto Murata, Kouichi Miura, Atsushi Tanaka, Tatsuya Kanto, Michinori Kohara, Terumi Kamisawa, Kiminori Kimura
Publikováno v:
Hepatology Communications, Vol 6, Iss 10, Pp 2732-2747 (2022)
Abstract Chronic cholestatic liver diseases are characterized by injury of the bile ducts and hepatocytes caused by accumulated bile acids (BAs) and inflammation. Wnt/β‐catenin signaling is implicated in organ fibrosis; however, its role in choles
Externí odkaz:
https://doaj.org/article/d5276f048b864db68f6d4c442a93004d
Autor:
Kazane Sugiyama, Kana Iijima, Miyako Yoshino, Hideo Dohra, Yuji Tokimoto, Koji Nishikawa, Hideaki Idogaki, Nobuyuki Yoshida
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract Nicotinamide mononucleotide (NMN), an intermediate in nicotinamide adenine dinucleotide biosynthesis, is recently attracting much attention for its pharmacological and anti-aging efficacies. However, current commercial products containing NM
Externí odkaz:
https://doaj.org/article/69217ad54c3d43968ea789c729692bf6
Autor:
Kiminori Kimura, Tatsuya Kanto, Shinji Shimoda, Kenichi Harada, Masamichi Kimura, Koji Nishikawa, Jun Imamura, Eiichi Ogawa, Masanao Saio, Yoshihiro Ikura, Takuji Okusaka, Kazuaki Inoue, Tetsuya Ishikawa, Ichiro Ieiri, Junji Kishimoto, Koji Todaka, Terumi Kamisawa
Publikováno v:
EBioMedicine, Vol 80, Iss , Pp 104069- (2022)
Summary: Background: We conducted an exploratory study to assess the safety tolerability, and anti-fibrotic effects of PRI-724, a CBP/β-catenin inhibitor, in patients with hepatitis C virus (HCV)- and hepatitis B virus (HBV)-induced cirrhosis. Metho
Externí odkaz:
https://doaj.org/article/a68a8544980a4b5a8162b15098cfe871
Publikováno v:
Journal of Infection and Chemotherapy. 29:263-268
The high prevalence of hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-positive men who have sex with men (MSM) is an important health issue. The purpose of this study is to investigate the actual prevalence of HCV infection a
Autor:
Yasuhiro Higashi, Shinichi Takabatake, Asako Matsubara, Koji Nishikawa, Toshikatsu Kaneda, Kazuyo Nakaoka, Yuta Somei, Guðrún Árnadóttir
Publikováno v:
Asian Journal of Occupational Therapy. 19:30-37
Publikováno v:
American Journal of Case Reports. 24
Autor:
Kiminori Kimura, Akemi Ikoma, Maki Shibakawa, Shinji Shimoda, Kenichi Harada, Masanao Saio, Jun Imamura, Yosuke Osawa, Masamichi Kimura, Koji Nishikawa, Takuji Okusaka, Satoshi Morita, Kazuaki Inoue, Tatsuya Kanto, Koji Todaka, Yoichi Nakanishi, Michinori Kohara, Masashi Mizokami
Publikováno v:
EBioMedicine, Vol 23, Iss C, Pp 79-87 (2017)
Background: There is currently no anti-fibrotic drug therapy available to treat hepatitis C virus (HCV) cirrhosis. The aim of this study was to assess the safety, tolerability, and anti-fibrotic effect of PRI-724, a small-molecule modulator of Wnt si
Externí odkaz:
https://doaj.org/article/17a6c1e0f18841c184e14890ad5fd895